All In Biotech

Free tool

FAERS Monitor: Rezenopy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215487 or its brand name (Rezenopy, Naloxone Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

809

Serious

510

63% of reports

Hospitalization

284

Death reported

100

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue90
  • nausea73
  • headache54
  • drug ineffective52
  • diarrhoea51
  • off label use50
  • pain50
  • death47
  • dyspnoea47
  • product dose omission issue46
  • asthenia37
  • rash36
  • decreased appetite34
  • pneumonia33
  • arthralgia32

Reports by year received

View as table
YearReports
20043
20054
20063
20071
20081
20096
20115
201215
20131
20143
20153
201610
201719
201835
201941
202049
202128
202258
2023120
2024128
2025157
2026119

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,350 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product dose omission issueSignal464.13.1105
decreased appetiteSignal343.82.768
fatigueSignal903.02.5123
pneumoniaSignal332.71.933
astheniaSignal372.61.934
nauseaSignal732.41.960
headacheSignal542.21.737
dyspnoeaSignal472.21.629
rashSignal362.11.621
painSignal502.11.629
diarrhoeaSignal512.11.627
arthralgiaSignal322.01.415
off label use501.51.18
death471.41.16
drug ineffective521.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.